Zynerba Pharmaceuticals, Inc operates as a clinical stage specialty pharmaceutical company. It focuses on developing pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. The company is developing Zygel, a transdermal cannabidiol gel, which is in Phase II clinical trial for treating children and adolescent patients with developmental and epileptic encephalopathies; is in Phase II/III clinical trial to treat children and adolescent patients with fragile X syndrome; and is in Phase II clinical trial for treating children and adolescent patients with autism spectrum disorder.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone484-581-7505
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$90,000.00
Profitability
Miscellaneous
Employees25
Next Earnings Date11/14/2019 (Estimated)
OptionableOptionable
Zynerba Pharmaceuticals (NASDAQ:ZYNE) Frequently Asked Questions
What is Zynerba Pharmaceuticals' stock symbol?
Zynerba Pharmaceuticals trades on the NASDAQ under the ticker symbol "ZYNE."
How were Zynerba Pharmaceuticals' earnings last quarter?
Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) announced its quarterly earnings data on Tuesday, August, 6th. The company reported ($0.50) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.50) by $0.01. View Zynerba Pharmaceuticals' Earnings History.
When is Zynerba Pharmaceuticals' next earnings date?
What price target have analysts set for ZYNE?
6 brokerages have issued 12-month target prices for Zynerba Pharmaceuticals' stock. Their forecasts range from $11.00 to $36.00. On average, they anticipate Zynerba Pharmaceuticals' share price to reach $22.67 in the next year. This suggests a possible upside of 181.9% from the stock's current price. View Analyst Price Targets for Zynerba Pharmaceuticals.
What is the consensus analysts' recommendation for Zynerba Pharmaceuticals?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zynerba Pharmaceuticals in the last year. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Zynerba Pharmaceuticals.
What are Wall Street analysts saying about Zynerba Pharmaceuticals stock?
Here are some recent quotes from research analysts about Zynerba Pharmaceuticals stock:
- 1. LADENBURG THALM/SH SH analysts commented, "We understand the market’s reaction when focusing on a few items: 1) There was a case of status epilepticus (SE); 2) 96% of patients reported an adverse event (AE); 3) 10/48 (21%) reported a serious adverse event (SAE); 4) Zygel doesn’t work fast enough; 5) 7 of 48 (15%) dropped out for efficacy; and 6) There were only 11 Dravet syndrome (DS) and Lennox-Gastaut syndrome (LGS) patients. However, we find some perspective on these figures are important to consider: 1. SE has not been found in any previous Zygel trial, including the Phase 2s in adult refractory epilepsy (n=188), osteoarthritis of the knee (n=300) and Fragile X syndrome (FXS; n=16). As we have described in our notes on Buy), SE typically occurs in patients highly compromised by underlying health conditions and/or trauma." (9/18/2019)
- 2. According to Zacks Investment Research, "Zynerba Pharmaceuticals, Inc. is a specialty pharmaceutical company which focuses on developing and commercializing proprietary synthetic cannabinoid therapeutics formulated for transdermal delivery. Its product candidates which are in clinical trial stage include ZYN002 and ZYN001 synthetic transdermal cannabinoid therapeutics for indications including refractory epilepsy, Fragile X syndrome, osteoarthritis, fibromyalgia and peripheral neuropathic pain. Zynerba Pharmaceuticals, Inc. is headquartered in Devon, Pennsylvania. " (6/8/2019)
- 3. Cantor Fitzgerald analysts commented, "We rate ZYNE Overweight. We focus our valuation on FXS, where we are encouraged by the open-label, long-term data, with meaningful and durable improvements that we see having predictive value for the pbo-controlled pivotal CONNECT-FX trial. On epilepsy indications, we await further data after a disappointment in focal epilepsy. Section may be found on pages 4 – 5.We use a discounted NPV revenue calculation that yields ~$8 for ZYN002 in the U.S. FXS market and ~$3 in the EU." (3/7/2019)
Has Zynerba Pharmaceuticals been receiving favorable news coverage?
News coverage about ZYNE stock has been trending negative recently, according to InfoTrie Sentiment. InfoTrie identifies positive and negative press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Zynerba Pharmaceuticals earned a news sentiment score of -2.0 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View News Stories for Zynerba Pharmaceuticals.
Are investors shorting Zynerba Pharmaceuticals?
Zynerba Pharmaceuticals saw a drop in short interest in September. As of September 15th, there was short interest totalling 4,280,000 shares, a drop of 7.2% from the August 15th total of 4,610,000 shares. Based on an average daily volume of 1,180,000 shares, the short-interest ratio is currently 3.6 days. Approximately 21.1% of the company's stock are sold short. View Zynerba Pharmaceuticals' Current Options Chain.
Who are some of Zynerba Pharmaceuticals' key competitors?
Some companies that are related to Zynerba Pharmaceuticals include Principia Biopharma (PRNB), Omeros (OMER), Axsome Therapeutics (AXSM), Vanda Pharmaceuticals (VNDA), Wave Life Sciences (WVE), Rhythm Pharmaceuticals (RYTM), Organogenesis (ORGO), Stoke Therapeutics (STOK), Kura Oncology (KURA), Emisphere Technologies (EMIS), Vectura Group (VEGPF), Cytokinetics (CYTK), Karyopharm Therapeutics (KPTI), Revance Therapeutics (RVNC) and Rocket Pharmaceuticals (RCKT).
What other stocks do shareholders of Zynerba Pharmaceuticals own?
Who are Zynerba Pharmaceuticals' key executives?
Zynerba Pharmaceuticals' management team includes the folowing people:
- Mr. Armando Anido M.B.A., MBA, Chairman & CEO (Age 61)
- Ms. Terri B. Sebree, Pres (Age 61)
- Mr. James E. Fickenscher, CFO, VP of Corp. Devel. & Treasurer (Age 55)
- Mr. William C. Roberts, VP of Investor Relations & Corp. Communications (Age 50)
- Ms. Suzanne M. Hanlon, Sec., VP & Gen. Counsel (Age 62)
When did Zynerba Pharmaceuticals IPO?
(ZYNE) raised $42 million in an initial public offering (IPO) on Wednesday, August 5th 2015. The company issued 3,000,000 shares at $13.00-$15.00 per share. Jefferies and Piper Jaffray served as the underwriters for the IPO and Canaccord Genuity and Oppenheimer & Co. were co-managers.
Who are Zynerba Pharmaceuticals' major shareholders?
Zynerba Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional investors include Zeke Capital Advisors LLC (1.73%), Campbell Capital Management Inc. (0.48%) and Sterling Investment Advisors Ltd. (0.05%). Company insiders that own Zynerba Pharmaceuticals stock include Armando Anido, James E Fickenscher, John P Butler, Michael Rapp and Terri B Sebree. View Institutional Ownership Trends for Zynerba Pharmaceuticals.
Which major investors are selling Zynerba Pharmaceuticals stock?
Which major investors are buying Zynerba Pharmaceuticals stock?
ZYNE stock was purchased by a variety of institutional investors in the last quarter, including Campbell Capital Management Inc. and Sterling Investment Advisors Ltd.. Company insiders that have bought Zynerba Pharmaceuticals stock in the last two years include Armando Anido, James E Fickenscher, John P Butler, Michael Rapp and Terri B Sebree. View Insider Buying and Selling for Zynerba Pharmaceuticals.
How do I buy shares of Zynerba Pharmaceuticals?
Shares of ZYNE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Zynerba Pharmaceuticals' stock price today?
One share of ZYNE stock can currently be purchased for approximately $8.04.
How big of a company is Zynerba Pharmaceuticals?
Zynerba Pharmaceuticals has a market capitalization of $186.53 million and generates $90,000.00 in revenue each year. The company earns $-39,910,000.00 in net income (profit) each year or ($2.61) on an earnings per share basis. Zynerba Pharmaceuticals employs 25 workers across the globe.View Additional Information About Zynerba Pharmaceuticals.
What is Zynerba Pharmaceuticals' official website?
How can I contact Zynerba Pharmaceuticals?
Zynerba Pharmaceuticals' mailing address is 80 W. LANCASTER AVENUE SUITE 300, DEVON PA, 19333. The company can be reached via phone at 484-581-7505 or via email at [email protected]
MarketBeat Community Rating for Zynerba Pharmaceuticals (NASDAQ ZYNE)
MarketBeat's community ratings are surveys of what our community members think about Zynerba Pharmaceuticals and other stocks. Vote "Outperform" if you believe ZYNE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ZYNE will underperform the S&P 500 over the long term. You may vote once every thirty days.
